Expertise in
12
conditions

Dr. Carl E. Allen

Hematology | Oncology
Office
1102 Bates Ave Ste 750, 
Houston, TX 
Accepting New Patients
Expertise in
12
conditions
Office
1102 Bates Ave Ste 750, 
Houston, TX 

Overview

Carl Allen is a Hematologist and an Oncologist practicing medicine in Houston, Texas.

Dr. Allen is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Hemophagocytic Lymphohistiocytosis, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 160 peer reviewed articles and participating in 6 clinical trials. Dr. Allen is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
1102 Bates Ave Ste 750, Houston, TX 77030

Additional Areas of Focus

Dr. Allen has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Prednisone, Vinblastine, Mercaptopurine, Indomethacin, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, Intravenous immunoglobulin
Study Phase: Phase 2/Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Enrollment Status: Completed
Publish Date: February 05, 2025
Intervention Type: Drug, Other
Study Drugs: Selumetinib, Selumetinib Sulfate
Study Phase: Phase 2
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Emapalumab
Study Phase: Phase 3
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 4 Less Clinical Trials

159 Total Publications

Addendum: RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions.
Addendum: RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions.
Journal: The Journal of experimental medicine
Published: July 24, 2026
Similar Doctors
Expertise in
27
conditions
Dr. William G. Wierda
Hematology | Oncology
Expertise in
27
conditions
Dr. William G. Wierda
Hematology | Oncology
Referral may be required

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.1 miles away)
713-792-7040
Languages Spoken:
English
See accepted insurances

William Wierda is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Wierda is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
21
conditions
Dr. Murali M. Chintagumpala
Hematology | Oncology
Expertise in
21
conditions
Dr. Murali M. Chintagumpala
Hematology | Oncology
Referral may be required

Baylor College Of Medicine

6701 Fannin St, 
Houston, TX 
 (0.1 miles away)
832-822-4242
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Murali Chintagumpala is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Chintagumpala is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Gliomatosis Cerebri, Brain Tumor, Posterior Fossa Tumor, and Nephrectomy. Dr. Chintagumpala is currently accepting new patients.

Expertise in
8
conditions
Dr. Olive S. Eckstein
Hematology | Oncology
Expertise in
8
conditions
Dr. Olive S. Eckstein
Hematology | Oncology
Referral may be required

Baylor College Of Medicine

6701 Fannin St, 
Houston, TX 
 (0.1 miles away)
832-822-4242
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Olive Eckstein is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Eckstein is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Hemophagocytic Lymphohistiocytosis. Dr. Eckstein is currently accepting new patients.

Frequently Asked Questions about Dr. Carl E. Allen

How do I make an appointment with Dr. Carl E. Allen?

You can book an appointment with Dr. Carl E. Allen by calling their office at 832-824-4312. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Carl E. Allen a top-rated expert for Langerhans Cell Histiocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Carl E. Allen is classified as an Elite expert for Langerhans Cell Histiocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Carl E. Allen specialize in?

While Dr. Carl E. Allen is a Hematology, they have specific expertise in Langerhans Cell Histiocytosis, Reticulohistiocytoma, and Histiocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Carl E. Allen participate in research or clinical trials?

Yes. Dr. Carl E. Allen has published 159 articles and abstracts on conditions like Langerhans Cell Histiocytosis. You can view a list of Dr. Carl E. Allen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Carl E. Allen accept my insurance?

Dr. Carl E. Allen accepts most major insurance plans, including Friday Health and Humana. We recommend calling the office directly at 832-824-4312 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Allen's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile